EnteraGam® HIV Enteropathy Clinical Study Results
- EnteraGam® significantly decreased stool frequency and steadily improved stool consistency1,*
- Patients taking EnteraGam® had 4 fewer bowel movements per day, as well as improved consistency
- Mucosal CD4+ lymphocyte densities increased by a median of 140 cells/mm2, an increase of 51%
Median Changes From Baseline to End of Study1,*,†
|All patients experienced marked improvements in daily GI-related symptoms in as early as 3 weeks1|
No serious adverse events or drug interactions have been
reported with EnteraGam®2
*Results from an 8-week, open-label study of EnteraGam® in patients who had severe HIV-associated enteropathy (N = 8)
with approximately 5 to 6 watery stools per day. Subjects received 2.5 g of EnteraGam® twice daily.
†GI symptom questionnaire assessed cramping, urgency, incontinence, and nocturnal diarrhea with
a possible score of 0 to 24, with < 2 being normal.
‡Using a scale of 1 (formed) to 6 (watery).